Nona Biosciences has announced a research collaboration with the Medical University of Vienna (MedUni Vienna). The collaboration enables the inter-university Ignaz Semmelweis Institute–directed by Prof. Florian Krammer–to leverage Nona's proprietary H2L2 Harbour Mice platform for generating fully human antibodies to support a range of Research and Development (R&D) programs for infectious diseases.

Under the agreement, MedUni Vienna is granted the right to use Nona's technology for antibody generation and to further develop the resulting antibodies and antibody products for research, diagnostic, and therapeutic applications. The H2L2 Harbour Mice platform and all associated Intellectual Property (IP) rights remain vested in Nona Biosciences.

Dr. Di Hong, Chief Executive Officer (CEO), Nona Biosciences, said, "We are delighted to partner with the Medical University of Vienna. This collaboration underscores the power of our H2L2 Harbour Mice platform to accelerate the discovery of fully human antibodies against clinically relevant targets. By combining our technology with the scientific expertise of Prof. Krammer and his team at the Ignaz Semmelweis Institute, we aim to make meaningful contributions to antiviral therapeutic development and pandemic preparedness."

Antibodies play a vital role in modern medicine and form the basis of numerous diagnostic applications and biotechnologically produced therapies. Nona's H2L2 Harbour Mice technology is based on genetically modified mice that, following immunisation, produce antibodies with fully human structures. This enables fully human antibody candidates to be obtained and developed for further scientific investigation and potential medical applications.

Florian Krammer, Professor of Infectious Diseases, MedUni Vienna and Director of the inter-university Ignaz Semmelweis Institute, said, "Access to this technology expands our capabilities to generate and characterise human antibodies against relevant biological targets, particularly viral spike proteins. This provides us with an additional foundation for the development of antiviral therapies, particularly with a view to future pandemics."